DDInter1294 DDInter126
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase.
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Prednisone
Prednisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Eltrombopag
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is palliated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Axitinib
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide (Compound) resembles Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Eltrombopag (Compound) and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is palliated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi